Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2009 1
2016 1
2019 2
2021 2
2022 4
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment.
Kim DK, Synn CB, Yang SM, Kang S, Baek S, Oh SW, Lee GJ, Kang HW, Lee YS, Park JS, Kim JH, Byeon Y, Kim YS, Lee DJ, Kim HW, Park JD, Lee SS, Lee JY, Lee JB, Kim CG, Hong MH, Lim SM, Kim HR, Pyo KH, Cho BC. Kim DK, et al. Front Chem. 2022 Dec 5;10:998013. doi: 10.3389/fchem.2022.998013. eCollection 2022. Front Chem. 2022. PMID: 36545214 Free PMC article.
Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity.
Lee W, Kim DK, Synn CB, Lee HK, Park S, Jung DS, Choi Y, Kim JH, Byeon Y, Kim YS, Lee S, Lee S, Joo Y, Lee EJ, Yun MR, Heo SG, Yang W, Jung JE, Kim EK, Park J, Park JD, Lee DJ, Kim HW, Lim SM, Hong MH, Ahn BC, Lee JB, Pyo KH. Lee W, et al. Among authors: kim dk. Front Oncol. 2022 Mar 9;12:821391. doi: 10.3389/fonc.2022.821391. eCollection 2022. Front Oncol. 2022. PMID: 35356198 Free PMC article.
SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models.
Synn CB, Kim SE, Lee HK, Kim MH, Kim JH, Lee JM, Jo HN, Lee W, Kim DK, Byeon Y, Kim YS, Yun MR, Park CW, Yun J, Lim S, Heo SG, Yang SD, Lee EJ, Lee S, Choi H, Lee YW, Cho JS, Kim DH, Park S, Kim JH, Choi Y, Lee SS, Ahn BC, Kim CG, Lim SM, Hong MH, Kim HR, Pyo KH, Cho BC. Synn CB, et al. Among authors: kim dk. Clin Transl Immunology. 2021 Dec 29;11(1):e1364. doi: 10.1002/cti2.1364. eCollection 2022. Clin Transl Immunology. 2021. PMID: 35003748 Free PMC article.
Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer.
Ahn BC, So JW, Synn CB, Kim TH, Kim JH, Byeon Y, Kim YS, Heo SG, Yang SD, Yun MR, Lim S, Choi SJ, Lee W, Kim DK, Lee EJ, Lee S, Lee DJ, Kim CG, Lim SM, Hong MH, Cho BC, Pyo KH, Kim HR. Ahn BC, et al. Among authors: kim dk. Eur J Cancer. 2021 Aug;153:179-189. doi: 10.1016/j.ejca.2021.05.019. Epub 2021 Jun 26. Eur J Cancer. 2021. PMID: 34182269
CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production.
Na K, Lee S, Kim DK, Kim YS, Hwang JY, Kang SS, Baek S, Lee CY, Yang SM, Han YJ, Kim MH, Han H, Kim Y, Kim JH, Jeon S, Byeon Y, Lee JB, Lim SM, Hong MH, Pyo KH, Cho BC. Na K, et al. Among authors: kim dk. Front Immunol. 2024 Mar 7;15:1336246. doi: 10.3389/fimmu.2024.1336246. eCollection 2024. Front Immunol. 2024. PMID: 38515751 Free PMC article.
13 results